
Paul V. Ward
Examiner (ID: 13921, Phone: (571)272-2909 , Office: P/1624 )
| Most Active Art Unit | 1624 |
| Art Unit(s) | 1624, 1623, 1622 |
| Total Applications | 2552 |
| Issued Applications | 1846 |
| Pending Applications | 195 |
| Abandoned Applications | 548 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19112731
[patent_doc_number] => 20240124481
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => NEW COMPOUNDS AND METHODS OF THEIR MANUFACTURING
[patent_app_type] => utility
[patent_app_number] => 18/496043
[patent_app_country] => US
[patent_app_date] => 2023-10-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6585
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18496043
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/496043 | Compounds and methods of their manufacturing | Oct 26, 2023 | Issued |
Array
(
[id] => 19387854
[patent_doc_number] => 20240277724
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => COMBINATION THERAPY FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
[patent_app_type] => utility
[patent_app_number] => 18/383992
[patent_app_country] => US
[patent_app_date] => 2023-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11253
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18383992
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/383992 | Combination therapy for treatment of myeloproliferative neoplasms | Oct 25, 2023 | Issued |
Array
(
[id] => 19127152
[patent_doc_number] => 20240132505
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-25
[patent_title] => PYRROLOPYRIMIDINE ITK INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/383301
[patent_app_country] => US
[patent_app_date] => 2023-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 64776
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18383301
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/383301 | Pyrrolopyrimidine ITK inhibitors | Oct 23, 2023 | Issued |
Array
(
[id] => 19027251
[patent_doc_number] => 11926598
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-03-12
[patent_title] => 1-(4-nitrobenzylideneamino)-5-phenylimidazolidine-2,4-dione as an antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/382696
[patent_app_country] => US
[patent_app_date] => 2023-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 3978
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18382696
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/382696 | 1-(4-nitrobenzylideneamino)-5-phenylimidazolidine-2,4-dione as an antimicrobial compound | Oct 22, 2023 | Issued |
Array
(
[id] => 20343070
[patent_doc_number] => 12466792
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-11
[patent_title] => Compounds for the treatment of SARS
[patent_app_type] => utility
[patent_app_number] => 18/492411
[patent_app_country] => US
[patent_app_date] => 2023-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9187
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18492411
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/492411 | Compounds for the treatment of SARS | Oct 22, 2023 | Issued |
Array
(
[id] => 19027268
[patent_doc_number] => 11926615
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-03-12
[patent_title] => 2-alkoxy[4,3:6,4-terpyridine]-3-carbonitriles as antimicrobial compounds
[patent_app_type] => utility
[patent_app_number] => 18/484395
[patent_app_country] => US
[patent_app_date] => 2023-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4212
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18484395
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/484395 | 2-alkoxy[4,3:6,4-terpyridine]-3-carbonitriles as antimicrobial compounds | Oct 9, 2023 | Issued |
Array
(
[id] => 20172924
[patent_doc_number] => 12391655
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-08-19
[patent_title] => Melamine process with a two-stage purification of melamine offgas
[patent_app_type] => utility
[patent_app_number] => 18/710989
[patent_app_country] => US
[patent_app_date] => 2023-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 224
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 202
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18710989
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/710989 | Melamine process with a two-stage purification of melamine offgas | Oct 4, 2023 | Issued |
Array
(
[id] => 19112730
[patent_doc_number] => 20240124480
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => Compounds and Methods of Their Manufacturing
[patent_app_type] => utility
[patent_app_number] => 18/469860
[patent_app_country] => US
[patent_app_date] => 2023-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18469860
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/469860 | Compounds and methods of their manufacturing | Sep 18, 2023 | Issued |
Array
(
[id] => 20633401
[patent_doc_number] => 12594264
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-07
[patent_title] => Modulators of alpha-synuclein proteolysis and associated methods of use
[patent_app_type] => utility
[patent_app_number] => 18/309867
[patent_app_country] => US
[patent_app_date] => 2023-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 9
[patent_no_of_words] => 65578
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18309867
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/309867 | Modulators of alpha-synuclein proteolysis and associated methods of use | Sep 17, 2023 | Issued |
Array
(
[id] => 18895146
[patent_doc_number] => 20240010631
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-11
[patent_title] => CHEMICAL COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/467185
[patent_app_country] => US
[patent_app_date] => 2023-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33729
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18467185
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/467185 | Chemical compounds | Sep 13, 2023 | Issued |
Array
(
[id] => 18860100
[patent_doc_number] => 20230414534
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => USE OF TAPINAROF FOR THE TREATMENT OF ATOPIC DERMATITIS
[patent_app_type] => utility
[patent_app_number] => 18/459778
[patent_app_country] => US
[patent_app_date] => 2023-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52834
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459778
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/459778 | Use of tapinarof for the treatment of atopic dermatitis | Aug 31, 2023 | Issued |
Array
(
[id] => 18842539
[patent_doc_number] => 20230404943
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => CANNABINOID DOSING REGIME FOR DERMATITIS AND INFLAMMATORY SKIN CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 18/238442
[patent_app_country] => US
[patent_app_date] => 2023-08-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13433
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18238442
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/238442 | CANNABINOID DOSING REGIME FOR DERMATITIS AND INFLAMMATORY SKIN CONDITIONS | Aug 24, 2023 | Pending |
Array
(
[id] => 20644681
[patent_doc_number] => 12599606
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-04-14
[patent_title] => Therapies with 3rd generation EGFR tyrosine kinase inhibitors
[patent_app_type] => utility
[patent_app_number] => 18/453743
[patent_app_country] => US
[patent_app_date] => 2023-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 21850
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18453743
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/453743 | Therapies with 3rd generation EGFR tyrosine kinase inhibitors | Aug 21, 2023 | Issued |
Array
(
[id] => 18806789
[patent_doc_number] => 20230381120
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-30
[patent_title] => Treatment of Age-Related Macular Degeneration, Glaucoma, and Diabetic Retinopathy with N-Acetylcysteine Amide (NACA) or (2R,2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide)(DiNACA)
[patent_app_type] => utility
[patent_app_number] => 18/447720
[patent_app_country] => US
[patent_app_date] => 2023-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9302
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18447720
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/447720 | Treatment of Age-Related Macular Degeneration, Glaucoma, and Diabetic Retinopathy with N-Acetylcysteine Amide (NACA) or (2R,2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide)(DiNACA) | Aug 9, 2023 | Pending |
Array
(
[id] => 19096347
[patent_doc_number] => 20240115574
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN
IMMUNODEFICIENCY VIRUS INFECTION
[patent_app_type] => utility
[patent_app_number] => 18/446244
[patent_app_country] => US
[patent_app_date] => 2023-08-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16045
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18446244
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/446244 | INHIBITION OF nSMase FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION | Aug 7, 2023 | Abandoned |
Array
(
[id] => 18953574
[patent_doc_number] => 20240041901
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => WOUND TREATMENT TOPICAL COMPOSITION CONTAINING CANNABINOIDS
[patent_app_type] => utility
[patent_app_number] => 18/228881
[patent_app_country] => US
[patent_app_date] => 2023-08-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3934
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18228881
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/228881 | WOUND TREATMENT TOPICAL COMPOSITION CONTAINING CANNABINOIDS | Jul 31, 2023 | Pending |
Array
(
[id] => 19140370
[patent_doc_number] => 20240139149
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => THERAPEUTIC USES OF UROLITHIN DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 18/226621
[patent_app_country] => US
[patent_app_date] => 2023-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61036
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18226621
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/226621 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | Jul 25, 2023 | Pending |
Array
(
[id] => 19265244
[patent_doc_number] => 20240208943
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => POLYMORPHS OF SELINEXOR
[patent_app_type] => utility
[patent_app_number] => 18/226570
[patent_app_country] => US
[patent_app_date] => 2023-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32905
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18226570
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/226570 | Polymorphs of Selinexor | Jul 25, 2023 | Issued |
Array
(
[id] => 18739497
[patent_doc_number] => 20230348431
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
[patent_app_type] => utility
[patent_app_number] => 18/219511
[patent_app_country] => US
[patent_app_date] => 2023-07-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33931
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 207
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18219511
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/219511 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith | Jul 6, 2023 | Issued |
Array
(
[id] => 18724400
[patent_doc_number] => 20230338551
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/214825
[patent_app_country] => US
[patent_app_date] => 2023-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46441
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18214825
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/214825 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | Jun 26, 2023 | Issued |